Drug Discovery World

SEPTEMBER 21, 2022

Otsuka Pharmaceutical’s Lupkynis (voclosporin) is the first oral treatment to be approved in Europe for the treatment of active lupus nephritis (LN) in adult patients. LN is a severe manifestation of systemic lupus erythematosus (SLE), a chronic and debilitating autoimmune disease that is suggested to cause irreversible nephron loss.

Treatment 130

Treatment Licensing Licensing Pharmaceuticals 130

Drug Discovery World

MARCH 16, 2023

Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML. Around one third of patients with AML are diagnosed with FLT3-mutations, which are associated with a higher risk of relapse and poor clinical outcome. and Leung, A. International Journal of Molecular Science, 21(4): 1537. and Wang, H-G.

Treatment 130

Treatment FDA FDA Approval Drug Development 130

The Pharma Data

MAY 14, 2021

Product Name: Home – Beat Kidney Disease – 2020 – Beat Kidney Disease. Home – Beat Kidney Disease – 2020 – Beat Kidney Disease is backed with a 60 Day No Questions Asked Money Back Guarantee. This product is not intended to diagnose, treat, cure, or prevent any disease.

Disease 52

Disease Production Licensing Licensing 52

Drug Discovery World

OCTOBER 31, 2023

Professor Andy Whiting and Dr Tony Lockett discuss how specific levels of a protein could be used to advance drug development in neurodegenerative diseases. These parameters aim to measure the progression of disease over time by looking at the functional or observable change in a patient.

Drug Development 147

Drug Development Disease Drugs Clinical Trials 147

Drug Discovery World

DECEMBER 22, 2022

Shelley McLendon , SVP of Vaccine and Infectious Diseases Program Management at ICON, attended the World Vaccine Congress Europe from 16-19 October 2022 in Barcelona, Spain. Disease surveillance and reporting . Disease surveillance is the collection and monitoring of data on disease within a population.

Vaccine 130

Vaccine Disease Clinical Trials Trials 130

Drugs.com

JULY 6, 2023

Centers for Disease Control and Prevention estimates that there were nearly 68,000 new cases of acute hepatitis C in 2020 and over 107,000 newly reported cases of chronic hepatitis C? THURSDAY, July 6, 2023 -- Did you know the U.S. To help you.

Treatment 119

Treatment Disease 119

Drug Channels

NOVEMBER 2, 2020

Rare Disease Innovation and Partnering Summit 2020. December 1-4, 2020 | Virtual Event www.raredisease-summit.com. This December, tackle challenges faced in ensuring patient access and furthering therapeutic and curative progress at the Rare Disease Innovation & Partnering Summit. David Fajgenbaum, M.D.,

Disease 52

Disease FDA Pharmaceuticals Hospitals 52

Drug Discovery World

NOVEMBER 16, 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised the world’s first gene therapy for sickle-cell disease (SCD) and transfusion-dependent β-thalassemia (TDT). Of these eligible patients, 28 (97%) were free of severe pain crises for at least 12 months after treatment.

Therapies 277

Therapies Clinical Trials Trials Treatment 277

Eye on FDA

MARCH 7, 2024

Back in December 2023, FDA announced intention in the Federal Register and in a press release to form a new FDA Advisory Committee to be called the Genetic Metabolic Diseases Advisory Committee (GeMDAC).

FDA 78

FDA Disease Government Therapies 78

Drug Target Review

JUNE 8, 2023

An important research area at AbbVie involves blood cancers, where our ultimate goal is to transform standards of care across these diseases and advance a dynamic cancer research and treatment pipeline. 2 However, treatment options were still limited and often came with severe side effects.

Treatment 105

Treatment Organic Chemistry Research Disease 105

Drug Target Review

MAY 7, 2024

Why are biomarkers particularly critical in the context of rare diseases? Developing novel therapeutic approaches for rare diseases poses inherent challenges due to the limited populations available for testing. How do AI-enhanced approaches accelerate the drug development process for rare diseases?

Disease 59

Disease Clinical Trials Clinical Pharmacology Trials 59

SCIENMAG: Medicine & Health

JULY 5, 2023

New drugs are often used not only for one disease (first approved indication) but also for other diseases (supplemental indications).

Treatment 67

Treatment Drugs Disease 67

Drug Discovery World

AUGUST 14, 2024

This marks the first cell therapy to enter Phase lI trials in both the US and China for the treatment of relapsed/metastatic EBV-positive nasopharyngeal carcinoma. All patients are late-stage cancer patients failing standard treatment including checkpoint inhibitors.

Therapies 130

Therapies Trials Clinical Trials FDA 130

Drug Discovery World

MAY 3, 2024

SynOx Therapeutics has closed a $75m Series B financing round, which will be used to generate registrational Phase III clinical and CMC data for emactuzumab, the company’s potentially best-in-class CSF-1(R) inhibiting monoclonal antibody (mAb) for the treatment of tenosynovial giant cell tumour (TGCT).

Disease 130

Disease Therapies Trials Treatment 130

Drug Discovery World

JULY 2, 2024

It is recommended as a monotherapy to treat adult patients with unresectable or metastatic urothelial carcinoma, harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. months vs 7.8 months vs 2.7

Therapies 147

Therapies Treatment Production Disease 147

FDA Law Blog: Drug Discovery

DECEMBER 13, 2023

Sasinowski — On December 12, 2023, FDA announced the creation of a new advisory committee specifically for treatments for genetic metabolic diseases, the Genetic Metabolic Diseases Advisory Committee, or “GeMDAC.” There are hundreds of known genetic metabolic diseases, most of which are rare and carry significant morbidity.

Disease 59

Disease Production FDA Drug Development 59

DrugBank

JULY 20, 2023

of the global population) suffer from rare conditions without effective treatments or cures. Rare diseases, therefore, present compelling opportunities for Drug Development. Since each disease is present in small groups of patients, this research is also fraught with complex challenges. At any given time, millions of people ( 3.5–5.9%

Disease 76

Disease Clinical Trials Trials FDA 76

The Pharma Data

APRIL 7, 2022

It may also limit coverage for any future approved treatment in the class. These coverage restrictions, including the distinction between accelerated approval and traditional approval, have never been applied to FDA-approved medicines for other disease areas. ADUHELM is indicated for the treatment of Alzheimer’s disease.

Treatment 52

Treatment Therapies Disease FDA Approval 52

The Pharma Data

NOVEMBER 9, 2020

An experimental Alzheimer’s disease treatment should not be approved by the U.S. The drug, developed by the pharmaceutical company Biogen and its Japanese partner Eisai, is administered through intravenous infusion for early Alzheimer’s disease. © 2020 HealthDay. Posted: November 2020. Source link.

Pharmaceutical Companies 52

Pharmaceutical Companies Treatment FDA Disease 52

The Pharma Data

DECEMBER 30, 2020

The year 2020 will certainly go down in history as the year of COVID-19. Gilead Sciences Makes Multiple Bets : When Gilead Sciences wasn’t working on remdesivir in COVID-19, the company seemed to be constantly flexing its M&A muscle over the course of 2020. It began in May with the $4.9 But the U.K.-based

Science 52

Science Pharmaceuticals Disease FDA Approval 52

The Pharma Data

NOVEMBER 8, 2020

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. LONDON and RALEIGH, N.C., For more information, please visit www.veronapharma.com. Forward-Looking Statements.

Therapies 52

Therapies Treatment Disease Hospitals 52

The Pharma Data

OCTOBER 20, 2020

21, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. Eastern Time to discuss its third quarter 2020 financial results and report on pipeline and business progress. Webcast scheduled for Wednesday, November 4 at 11:30 a.m. Eastern Time. . CARLSBAD, Calif. , Interested parties may access the webcast at www.ionispharma.com.

RNA 52

RNA Pharmaceuticals Disease Treatment 52

Drug Discovery World

MARCH 10, 2023

The approval is in patients with locally advanced or metastatic urothelial cancer (la/mUC) who have received prior treatment with a PD-1/L1 inhibitor and platinum-based chemotherapy. “In In China, the incidence rate of bladder cancer in 2020 ranked 12th among all cancers, with an estimated 85,649 new cases that year.

Pharmacokinetics 130

Pharmacokinetics Drugs Licensing Licensing 130

The Pharma Data

NOVEMBER 18, 2020

Antimicrobial resistance occurs when microorganisms resist the effects of medications, making infections harder to treat and increasing the risk of disease spread, severe illness and death. Key definitions. Combatting antimicrobial resistance is a global. The strategy provides an overview of WHO-recommended. taking PrEP.

Laboratories 52

Laboratories Virus Government Therapies 52

The Pharma Data

JUNE 29, 2021

If approved, Forxiga has the potential to change the treatment paradigm for millions of people in the EU suffering from chronic kidney disease. CKD is a serious, progressive condition defined by decreased kidney function and is often associated with an increased risk of heart disease or stroke.

Treatment 52

Treatment Disease Trials Science 52

The Pharma Data

MARCH 28, 2022

Kerendia ™ (10 mg or 20 mg), a non-steroidal, selective mineralocorticoid receptor (MR) antagonist, is approved for the treatment of chronic kidney disease and type 2 diabetes, excluding patients with end-stage renal disease or on dialysis. Finerenone is different to existing CKD in T2D treatments.

Disease 52

Disease Treatment Clinical Trials Trials 52

Drug Discovery World

FEBRUARY 28, 2024

According to the American Association of Cancer Research (AACR) 2 , research-driven advances in treatments have resulted in the decline in death rates for melanoma, leukaemia, and kidney cancer. Currently, all antibodies approved for the treatment of cancer belong to a class known as IgG. Research into new cancer drugs remain strong.

Drug Development 162

Drug Development Research Clinical Trials Drugs 162

The Pharma Data

JULY 12, 2021

Finerenone 10 mg or 20 mg is indicated to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

FDA Approval 52

FDA Approval Disease FDA Treatment 52

The Pharma Data

JANUARY 12, 2021

(NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported preliminary unaudited fourth quarter 2020 revenue. million to $48.9 million to $48.9 About Inari Medical, Inc. Inari Medical, Inc.

FDA 52

FDA Production Treatment Disease 52

The Pharma Data

OCTOBER 26, 2020

27, 2020 (GLOBE NEWSWIRE) — Prevail Therapeutics Inc. Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the U.S. NEW YORK, Oct. Founder and Chief Executive Officer of Prevail. “FDA

FDA 40

FDA Disease Treatment Therapies 40

The Pharma Data

NOVEMBER 30, 2020

30, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. NASDAQ: REGN) will host a webcast on Monday, December 7, 2020 at 4:30pm EST. Management will discuss data presented at the American Society of Hematology (ASH) 2020 Annual Meeting as well as provide updates on the Company’s broader oncology and hematology portfolio.

FDA Approval 52

FDA Approval Laboratories Pharmaceuticals Disease 52

The Pharma Data

SEPTEMBER 28, 2020

Although Chagas disease was discovered more than a century ago, it remains a major public health challenge. Chagas disease affects approximately six million people, mainly in Latin America. Like other neglected tropical diseases, Chagas disease often affects poor and marginalized communities. Chagas Disease.

Disease 52

Disease Treatment 52

The Pharma Data

DECEMBER 30, 2020

The Feverish Pricing of MS Treatments. Towards the end of March, the FDA approved two new treatments for multiple sclerosis (MS): Mayzent (siponimod) and Mavenclad (cladribine). Drug treatments for MS have been climbing an expensive staircase for a number of years. Posted: December 2020. Consumer News. Source link.

Treatment 52

Treatment FDA Approval Disease FDA 52

The Pharma Data

OCTOBER 27, 2020

28, 2020 /PRNewswire/ — ReVision Therapeutics, Inc., 28, 2020 /PRNewswire/ — ReVision Therapeutics, Inc., Stargardt disease is a devastating genetic disorder that affects central vision with no approved treatment options. . RIDGEWOOD, N.J. , About reVision Therapeutics, Inc.

Disease 52

Disease Treatment FDA Licensing 52

The Pharma Data

OCTOBER 27, 2020

28, 2020 (GLOBE NEWSWIRE) — Passage Bio, Inc. Food and Drug Administration (FDA) has granted Orphan Drug and Rare Pediatric Disease (RPD) designations to PBKR03 for the treatment of Krabbe disease (Globoid Cell Leukodystrophy). About Krabbe Disease. PHILADELPHIA, Oct.

Disease 40

Disease FDA Treatment Clinical Trials 40

The Pharma Data

OCTOBER 15, 2020

Vertex Pharmaceuticals has decided to give up on its experimental VX-814, a small molecule drug for the rare genetic disease Alpha-1 antitrypsin deficiency (AATD), canning the drug’s development after seeing lackluster results from an early phase 2 trial. James Miessler.

Disease 52

Disease Small Molecule Pharmacokinetics Licensing 52

The Pharma Data

MARCH 24, 2021

billion EUR in 2020 (18.9% Boehringer Ingelheim stepped up its investments in R&D significantly in 2020 in pursuit of innovative medicines and therapies for diseases for which no satisfactory treatments are available. Our achievements in 2020 are the result of their effort.”. of net sales). billion EUR).

Vaccine 52

Vaccine Small Molecule Therapies Disease 52